«. Epidémiologie,

D. Sur,

, « Projection de l'incidence et de la mortalité par cancer en France métropolitaine en, Maladies chroniques et traumatismes / Rapports et synthèses / Publications et outils / Accueil, 2017.

D. Sur,

, de-la-mortalite-par-cancer-en-France-metropolitaine-en-2017

«. Oms-|-cancer, ». , and W. ,

D. Sur,

, « Cancer | LEEM -Les entreprises du médicament

D. Sur,

, « Le cancer en chiffres | Fondation ARC pour la recherche sur le cancer

, Disponible sur: /le-cancer-en-chiffres

«. Oms-|, Prévention du cancer

D. Sur,

J. Bryere, O. Dejardin, L. Launay, M. Colonna, P. Grosclaude et al., Réseau français des registres des cancers (Francim)., « Environnement socioéconomique et incidence des cancers en France, Bull Epidémiol Hebd, issue.4, pp.68-77, 2017.

D. Hanahan and R. A. Weinberg, « The Hallmarks of Cancer, vol.100, pp.57-70, 2000.

G. P. Dunn, A. T. Bruce, H. Ikeda, L. J. Old, and R. D. Schreiber, « Cancer immunoediting: from immunosurveillance to tumor escape, Nat Immunol, vol.3, issue.11, pp.991-998, 2002.

G. M. Cooper, The Eukaryotic Cell Cycle, 2000.

K. J. Barnum and M. J. O'connell, « Cell Cycle Regulation by Checkpoints », vol.1170, pp.29-40, 2014.

A. M. Narasimha, M. Kaulich, G. S. Shapiro, Y. J. Choi, P. Sicinski et al., « Cyclin D activates the Rb tumor suppressor by mono-phosphorylation, vol.3, 2014.

Z. Pan and X. Xie, « BRCA mutations in the manifestation and treatment of ovarian cancer, Oncotarget, vol.8, pp.97657-97670, 2017.

K. Oktay, V. Turan, S. Titus, R. Stobezki, L. Liu et al., DNA Repair Deficiency, and Ovarian Aging, vol.93, issue.3, 2015.

G. Liu and X. Chen, « Regulation of the p53 transcriptional activity, J. Cell. Biochem, vol.97, issue.3, pp.448-458, 2006.

T. Van-dyke, «. , and T. Suppression, New England Journal of Medicine, vol.356, issue.1, pp.79-81, 2007.

C. Slack, « Ras signaling in aging and metabolic regulation, Nutr Healthy Aging, vol.4, pp.195-205

M. Scaltriti, « Expression of p95HER2, a Truncated Form of the HER2 Receptor, and Response to Anti-HER2 Therapies in Breast Cancer, J Natl Cancer Inst, vol.99, issue.8, pp.628-638, 2007.

, « Les cancers en France en 2016 -L'essentiel des faits et chiffres -Ref : ETKAFRSYN16 | Institut National Du Cancer

. «-recherche and ». Développement,

D. Sur,

C. Davis, H. Naci, E. Gurpinar, E. Poplavska, A. Pinto et al., « Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals, BMJ, vol.359, issue.13, p.4530, 2009.

. «-observatoire-cancer,

D. Sur,

. «-médecine-personnalisée and . La-médecine-de-demain-|-roche,

D. Sur,

«. Inserm, Medecine personnalisee medecine du futur

D. Sur,

, Médecine personnalisée et thérapies ciblées pour traiter les pathologies graves

D. Sur,

, « Les thérapies ciblées dans le traitement du cancer, état des lieux en 2015 et enjeux, 2016.

M. J. Cross, J. Dixelius, T. Matsumoto, and L. Claesson-welsh, « VEGF-receptor signal transduction », Trends in Biochemical Sciences, vol.28, issue.9, pp.488-494, 2003.

, Immunothérapie : la révolution attendue contre le cancer », Institut Curie

D. Sur,

S. Deweerdt and . Bacteriology, A caring culture, Nature, vol.504, pp.4-5

«. Immunothérapie, mode d'action -Thérapies ciblées et immunothérapie spécifique | Institut National Du Cancer

K. M. Mahoney, G. J. Freeman, and D. F. Mcdermott, The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma, vol.37, pp.764-782, 2015.

F. Tang and P. Zheng, « Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?, Cell Biosci, vol.8, 2018.

J. Couzin-frankel, Cancer Immunotherapy », Science, vol.342, pp.1432-1433

H. Kantarjian, Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia, vol.376, pp.836-847, 2017.

J. Banchereau, K. Palucka, and . Immunotherapy, Cancer vaccines on the move », Nature Reviews Clinical Oncology, 2017.

Z. Hu, P. A. Ott, and C. J. Wu, « Towards personalized, tumour-specific, therapeutic vaccines for cancer, Nat Rev Immunol, vol.18, issue.3, pp.168-182, 2018.

, Fournier-Majoie Foundation, « Les biomarqueurs du cancer

D. Sur,

N. Rifai, M. A. Gillette, and S. A. Carr, « Protein biomarker discovery and validation: the long and uncertain path to clinical utility », Nature Biotechnology, vol.24, issue.8, pp.971-983, 2006.

R. Valdes and D. , Tyler) Yin, « Fundamentals of Pharmacogenetics in Personalized, Precision Medicine », Clinics in Laboratory Medicine, vol.36, issue.3, pp.447-459, 2016.

«. Biomarqueurs and . Produits-de-santé--ansm, Agence nationale de sécurité du médicament et des produits de santé

K. K. Jain, Role of Biomarkers in Personalized Medicine, pp.91-97, 2015.

M. S. Pepe, « Phases of Biomarker Development for Early Detection of Cancer, J Natl Cancer Inst, vol.93, pp.1054-1061, 2001.

N. Wentzensen and S. Wacholder, « From Differences in Means between Cases and Controls to Risk Stratification: A Business Plan for Biomarker Development, Cancer Discov, vol.3, issue.2, pp.148-157, 2013.

R. Simon, . Sensitivity, P. Specificity, N. For-predictive, and . Biomarkers, J Natl Cancer Inst, vol.107, issue.8, 2015.

, « Liste des tests de génétique somatique réalisés par les plateformes de génétique moléculaire des cancers

, « Plateformes hospitalières de génétique moléculaire des cancers : faits marquants et synthèse d'activité 2013 -Ref : BILPTFMOL14 | Institut National Du Cancer

D. Sur,

R. A. Burrell and C. Swanton, « Tumour heterogeneity and the evolution of polyclonal drug resistance, Mol Oncol, vol.8, issue.6, pp.1095-1111, 2014.

C. E. Meacham and S. J. Morrison, Nature, vol.501, pp.328-337, 2013.

V. Almendro, « Inference of tumor evolution during chemotherapy by computational modeling and in situ analysis of genetic and phenotypic cellular diversity, Cell Rep, vol.6, issue.3, pp.514-527, 2014.

Y. Sun, A. Patel, P. Kumar, and Z. Chen, « Role of ABC transporters in cancer chemotherapy, Chin J Cancer, vol.31, issue.2, pp.51-57

G. Szakács, J. K. Paterson, J. A. Ludwig, C. Booth-genthe, and M. M. Gottesman, « Targeting multidrug resistance in cancer », Nature Reviews Drug Discovery, vol.5, issue.3, pp.219-234, 2006.

D. Hanahan and R. A. Weinberg, « Hallmarks of Cancer: The Next Generation, Cell, vol.144, issue.5, pp.646-674, 2011.

K. Shiga, M. Hara, T. Nagasaki, T. Sato, H. Takahashi et al., Cancer-Associated Fibroblasts: Their Characteristics and Their Roles in Tumor Growth », vol.7, pp.2443-2458, 2015.

F. R. Balkwill, M. Capasso, and T. Hagemann, « The tumor microenvironment at a glance, J Cell Sci, vol.125, issue.23, pp.5591-5596

M. Lewis and A. Merched, « Tumor-Associated Macrophages, Inflammation and Pathogenesis of Hepatocellular Carcinoma, Journal of Molecular and Genetic Medicine, vol.08, p.3, 2014.

A. Mantovani, A. Sica, and . Macrophages, innate immunity and cancer: balance, tolerance, and diversity, Current Opinion in Immunology, vol.22, issue.2, pp.231-237

K. Shirabe, « Role of tumor-associated macrophages in the progression of hepatocellular carcinoma, Surg Today, vol.42, issue.1, pp.1-7, 2011.

C. Holohan, S. V. Schaeybroeck, D. B. Longley, and P. G. Johnston, « Cancer drug resistance: an evolving paradigm », Nature Reviews Cancer, vol.13, issue.10, p.714, 2013.

I. Dagogo-jack and A. T. Shaw, « Tumour heterogeneity and resistance to cancer therapies », Nature Reviews Clinical Oncology, 2017.

«. La-recherche-fondamentale-|-», La recherche fondamentale | Inserm -La science pour la santé

, Recherche fondamentale > Définition | Fondation Synergie Lyon Cancer

D. Sur,

D. J. Adams, « The Valley of Death in anticancer drug development: a re-assessment », Trends Pharmacol Sci, vol.33, issue.4, pp.173-180, 2012.

F. Papaccio, F. Paino, T. Regad, G. Papaccio, V. Desiderio et al., Review: Cancer Cells, Cancer Stem Cells, and Mesenchymal Stem Cells: Influence in Cancer Development, Stem Cells Transl Med, vol.6, pp.2115-2125, 2017.

A. Eastman, « Improving anticancer drug development begins with cell culture: misinformation perpetrated by the misuse of cytotoxicity assays, Oncotarget, vol.8, issue.5, p.8854, 2017.

, « Le développement préclinique ou la première évaluation | LEEM -Les entreprises du médicament

D. Sur,

T. Hartung, Thoughts on limitations of animal models, vol.14, pp.81-83, 2008.

M. B. Bracken, « Why animal studies are often poor predictors of human reactions to exposure, J R Soc Med, vol.102, issue.3, pp.120-122, 2009.

B. Seruga, A. Ocana, E. Amir, and I. F. Tannock, « Failures in Phase III: Causes and Consequences », vol.21, pp.4552-4560, 2015.

H. Qiu, Y. Min, Z. Rodgers, L. Zhang, and A. Z. Wang, Nanomedicine approaches to improve cancer immunotherapy, vol.9, 2017.

D. A. Balazs and W. T. Godbey, « Liposomes for Use in Gene Delivery, J Drug Deliv, vol.2011, 2011.

D. Afonso, « Triggering bilayer to inverted-hexagonal nanostructure formation by thiol-ene click chemistry on cationic lipids: consequences on gene transfection, Soft Matter, vol.12, pp.4516-4520, 2016.

Q. Xu, « Impact of Surface Polyethylene Glycol (PEG) Density on Biodegradable Nanoparticle Transport in Mucus ex vivo and Distribution in vivo, ACS Nano, vol.9, issue.9, pp.9217-9227, 2015.

J. Shi, P. W. Kantoff, R. Wooster, and O. C. Farokhzad, « Cancer nanomedicine: progress, challenges and opportunities, Nat Rev Cancer, vol.17, issue.1, pp.20-37, 2017.

D. Ibraheem, A. Elaissari, and H. Fessi, « Gene therapy and DNA delivery systems, International Journal of Pharmaceutics, vol.459, issue.1, pp.70-83, 2014.

D. P. Bartel and . Micrornas, Genomics, Biogenesis, Mechanism, and Function, vol.116, pp.281-297, 2004.

N. Cherradi, « microRNAs as Potential Biomarkers in Adrenocortical Cancer: Progress and Challenges, Front. Endocrinol, vol.6, 2016.

H. Schwarzenbach, N. Nishida, G. A. Calin, and K. Pantel, « Clinical relevance of circulating cell-free microRNAs in cancer, Nat Rev Clin Oncol, vol.11, issue.3, pp.145-156, 2014.

M. A. Cortez, C. Bueso-ramos, J. Ferdin, G. Lopez-berestein, A. K. Sood et al., MicroRNAs in body fluids-the mix of hormones and biomarkers, vol.8, p.467

R. Rupaimoole and F. J. Slack, « MicroRNA therapeutics: towards a new era for the management of cancer and other diseases », Nature Reviews Drug Discovery, vol.16, issue.3, pp.203-222, 2017.

J. F. Wiggins, « Development of a Lung Cancer Therapeutic Based on the Tumor Suppressor MicroRNA-34 », Cancer Res, vol.70, pp.5923-5930

C. Liu, « The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44 », Nature Medicine, vol.17, issue.2, pp.211-215, 2011.

P. Trang, « Systemic Delivery of Tumor Suppressor microRNA Mimics Using a Neutral Lipid Emulsion Inhibits Lung Tumors in Mice, Molecular Therapy, vol.19, issue.6, pp.1116-1122, 2011.

D. Yang, « Integrated Analyses Identify a Master MicroRNA Regulatory Network for the Mesenchymal Subtype in Serous Ovarian Cancer, Cancer Cell, vol.23, issue.2, pp.186-199, 2013.

M. Nishimura, « Therapeutic Synergy between microRNA and siRNA in Ovarian Cancer Treatment, Cancer Discov, vol.3, issue.11, pp.1302-1315, 2013.

R. Rupaimoole, « Hypoxia-upregulated microRNA-630 targets Dicer, leading to increased tumor progression, Oncogene, vol.35, pp.4312-4320, 2016.

P. Resnier, T. Montier, V. Mathieu, J. Benoit, and C. Passirani, « A review of the current status of siRNA nanomedicines in the treatment of cancer, Biomaterials, vol.34, pp.6429-6443, 2013.

S. W. Young, M. Stenzel, Y. Jia-lin, and «. Nanoparticle-sirna, A potential cancer therapy? », vol.98, pp.159-169, 2016.

S. J. Lee, « Co-delivery of VEGF and Bcl-2 dual-targeted siRNA polymer using a single nanoparticle for synergistic anti-cancer effects in vivo, Journal of Controlled Release, vol.220, pp.631-641, 2015.

A. Singh, P. Trivedi, and N. K. Jain, Advances in siRNA delivery in cancer therapy », Artificial Cells, vol.46, pp.274-283, 2018.

T. Wirth and S. Ylä-herttuala, « Gene Therapy Used in Cancer Treatment », Biomedicines, vol.2, issue.2, pp.149-162, 2014.

S. R. Wiley, Identification and characterization of a new member of the TNF family that induces apoptosis, vol.3, pp.673-682, 1995.

P. P. Guimarães, S. Gaglione, T. Sewastianik, R. D. Carrasco, R. Langer et al., « Nanoparticles for Immune Cytokine TRAIL-Based Cancer Therapy, ACS Nano, vol.12, issue.2, pp.912-931, 2018.

W. Song, C. Yan, Q. Zhou, and L. Zhen, « Galangin potentiates human breast cancer to apoptosis induced by TRAIL through activating AMPK, vol.89, pp.845-856, 2017.

L. Xu, « DR5-Cbl-b/c-Cbl-TRAF2 complex inhibits TRAIL-induced apoptosis by promoting TRAF2-mediated polyubiquitination of caspase-8 in gastric cancer cells, Mol Oncol, vol.11, pp.1733-1751, 2017.

R. W. Johnstone, A. J. Frew, and M. J. Smyth, « The TRAIL apoptotic pathway in cancer onset, progression and therapy », Nature Reviews Cancer, vol.8, issue.10, pp.782-798, 2008.

G. Picarda, « Preclinical Evidence that Use of TRAIL in Ewing's Sarcoma and Osteosarcoma Therapy Inhibits Tumor Growth, Prevents Osteolysis, and Increases Animal Survival, Clin Cancer Res, vol.16, issue.8, pp.2363-2374

R. Guiho, « TRAIL delivered by mesenchymal stromal/stem cells counteracts tumor development in orthotopic Ewing sarcoma models, International Journal of Cancer, vol.139, pp.2802-2811, 2016.

M. Sakisaka, « Therapy of primary and metastatic liver cancer by human iPS cellderived myeloid cells producing interferon-? », Journal of Hepato-Biliary-Pancreatic Sciences, vol.24, issue.2, pp.109-119, 2017.

D. Gomes-silva and C. A. Ramos, « Cancer immunotherapy using CAR-T cells: from the research bench to the assembly line, Biotechnol J, vol.13, issue.2, 2018.

J. Olweus, « Manufacture of CAR-T cells in the body », Nature Biotechnology, vol.35, issue.6, pp.520-521, 2017.

, The International SNP Map Working Group, « A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms, Nature, vol.409, pp.928-933, 2001.

F. Sanger, S. Nicklen, and A. R. Coulson, « DNA sequencing with chain-terminating inhibitors », Proc Natl Acad Sci U S A, vol.74, pp.5463-5467

L. Dortet, R. Bonnin, and T. Naas, Impact du séquençage d'ADN à haut débit sur la surveillance des épidémies de bactéries multi-résistantes aux antibiotiques, vol.354, 2017.

K. K. Jain and . Pharmacogenetics, Textbook of Personalized Medicine, pp.99-148, 2015.

R. Valdes and D. , Tyler) Yin, « Fundamentals of Pharmacogenetics in Personalized, Precision Medicine », juill, 2016.

, « Recherche d'un déficit en dihydropyrimidine déshydrogénase visant à prévenir certaines toxicités sévères associées aux traitements

M. E. Klein, .. M. Md, J. Parvez, and . Shin, « Clinical Implementation of Pharmacogenomics for Personalized Precision Medicine: Barriers and Solutions, Journal of Pharmaceutical Sciences, 2017.

K. K. Jain and . Pharmacogenomics, Textbook of Personalized Medicine, pp.149-158, 2015.

, Endopredict et Prosigna dans le cancer du sein de stade précoce, « Haute Autorité de Santé -Avis n° 2019.0003/AC/SEAP du 9 janvier 2019 du collège de la HAS relatif à l'inscription sur la LAP mentionnée à l'article L. 162-1-7 du CSS des signatures génomiques Oncotype Dx

N. M. Davis, « Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention, Oncotarget, vol.5, pp.4603-4650, 2014.

N. I. Pollock and J. R. Grandis, « HER2 as a Therapeutic Target in Head and Neck Squamous Cell Carcinoma, Clin Cancer Res, vol.21, issue.3, pp.526-533, 2015.

A. Jitariu, A. M. Cîmpean, D. Ribatti, and M. Raica, Triple negative breast cancer: the kiss of death, vol.8, pp.46652-46662, 2017.

A. Heimes and M. Schmidt, « Atezolizumab for the treatment of triple-negative breast cancer, Expert Opinion on Investigational Drugs, vol.28, issue.1, pp.1-5, 2019.

H. Katz and M. Alsharedi, « Immunotherapy in triple-negative breast cancer, Med Oncol, vol.35, issue.1, p.13, 2017.

L. A. Emens, « Breast Cancer Immunotherapy: Facts and Hopes, Clin Cancer Res, vol.24, issue.3, pp.511-520, 2018.

C. L. Scott, E. M. Swisher, S. H. Kaufmann, and . Poly, ADP-Ribose) Polymerase Inhibitors: Recent Advances and Future Development, J Clin Oncol, vol.33, pp.1397-1406, 2015.

A. R. Venkitaraman, Cancer Susceptibility and the Functions of BRCA1 and BRCA2, vol.108, pp.171-182, 2002.

N. Curtin and C. Szabo, Therapeutic Applications of PARP Inhibitors: Anticancer Therapy and Beyond, vol.34, 2013.

K. J. Rimar, P. T. Tran, R. S. Matulewicz, M. Hussain, and J. J. Meeks, « The Emerging Role of Homologous Recombination Repair and PARP Inhibitors in Genitourinary Malignancies, Cancer, vol.123, issue.11, pp.1912-1924, 2017.

B. O. Van-emburgh, « Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer, Nat Commun, vol.7, p.13665, 2016.

P. Saletti, F. Molinari, S. D. Dosso, and M. Frattini, « EGFR signaling in colorectal cancer: a clinical perspective, Gastrointestinal Cancer: Targets and Therapy, pp.19-2015

K. Matsuda and . Chapter, Based Detection Methods for Single-Nucleotide Polymorphism or Mutation: Real-Time PCR and Its Substantial Contribution Toward Technological Refinement, Advances in Clinical Chemistry, vol.80, pp.45-72, 2017.

M. Oettel, Handbook of Pharmaceutical Biotechnology, pp.1463-1489, 2006.

X. Wang, K. E. Kaczor-urbanowicz, D. T. Wong, and . Salivary, Biomarkers in Cancer Detection, vol.34, issue.1, 2017.

G. De-rubis, S. R. Krishnan, and E. M. Bebawy, Liquid Biopsies in Cancer Diagnosis, Monitoring, and Prognosis », vol.40, pp.172-186, 2019.

M. Yu, « Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition », Science, vol.339, pp.580-584, 2013.

S. Sharma, « Circulating tumor cell isolation, culture, and downstream molecular analysis, Biotechnology Advances, vol.36, issue.4, pp.1063-1078, 2018.

M. Yu, « Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility, Science, vol.345, pp.216-220, 2014.

P. Mandel and P. Metais, « Les acides nucléiques du plasma sanguin chez l'homme, C. R. Seances Soc. Biol. Fil, vol.142, pp.241-243, 1948.

, des résultats et des projets... », Institut Curie

F. Mouliere and N. Rosenfeld, « Circulating tumor-derived DNA is shorter than somatic DNA in plasma, Proceedings of the National Academy of Sciences of the United States of America, vol.112, pp.3178-3179, 2015.

F. Cheng, L. Su, and C. Qian, Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer, Oncotarget, vol.7, pp.48832-48841, 2016.

M. Stroun, « The Origin and Mechanism of Circulating DNA », Annals of the New York Academy of Sciences, vol.906, issue.1, pp.161-168, 2000.

J. M. Millholland, S. Li, C. A. Fernandez, and A. P. Shuber, « Detection of low frequency FGFR3 mutations in the urine of bladder cancer patients using next-generation deep sequencing, Res Rep Urol, vol.4, pp.33-40

L. and D. Mattos-arruda, « Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma, Nat Commun, vol.6, p.8839, 2015.

Y. Wang, « Detection of somatic mutations and HPV in the saliva and plasma of patients with head and neck squamous cell carcinomas, Sci Transl Med, vol.7, pp.293-104, 2015.

B. A. Lise and O. Østrup, « Toward liquid biopsies in cancer treatment: application of circulating tumor DNA, APMIS, vol.0, p.0

D. Pietrasz, Quel avenir pour l'ADN tumoral circulant ? État des lieux et perspectives dans les cancers colorectaux, pulmonaires non à petites cellules et pancréatiques », vol.103, pp.55-65, 2016.

M. Zendjabil, S. Favard, C. Tse, O. Abbou, and B. Hainque, Les microRNA comme biomarqueurs : quelles perspectives ? », Comptes Rendus Biologies

K. Vincent, M. Pichler, G. Lee, H. Ling, and . Micrornas, Genomic Instability and Cancer, Int J Mol Sci, vol.15, issue.8, pp.14475-14491, 2014.

D. Yu, Q. Li, X. Ding, Y. Ding, and C. Micrornas, Potential Biomarkers for Cancer, vol.12, issue.3, pp.2055-2063, 2011.

S. A. Melo, « Cancer Exosomes Perform Cell-Independent MicroRNA Biogenesis and Promote Tumorigenesis, Cancer Cell, vol.26, issue.5, pp.707-721, 2014.

H. Valadi, K. Ekström, A. Bossios, M. Sjöstrand, J. J. Lee et al., Exosomemediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells, Nat Cell Biol, vol.9, issue.6, pp.654-659, 2007.

J. Zhang, Exosome and Exosomal MicroRNA: Trafficking, Sorting, and Function, vol.13, pp.17-24, 2015.

J. Kowal, M. Tkach, and C. Théry, Biogenesis and secretion of exosomes, Current Opinion in Cell Biology, vol.29, pp.116-125, 2014.

W. Zhao, X. Zheng, and S. Zhao, Exosome and its roles in cardiovascular diseases, vol.20, pp.337-348, 2015.

S. Stuffers, C. Wegner, H. Stenmark, and A. Brech, Multivesicular Endosome Biogenesis in the Absence of ESCRTs », Traffic, vol.10, pp.925-937, 2009.

A. L. Revenfeld, R. Baek, M. H. Nielsen, A. Stensballe, K. Varming et al., Diagnostic and Prognostic Potential of Extracellular Vesicles in Peripheral Blood », Clinical Therapeutics, vol.36, issue.6, pp.830-846, 2014.

M. Tomasetti, W. Lee, L. Santarelli, and J. Neuzil, « Exosome-derived microRNAs in cancer metabolism: possible implications in cancer diagnostics and therapy », Exp Mol Med, vol.49, issue.1, p.285, 2017.

J. Lin, Novel Biomarkers for Clinical Diagnosis, ScientificWorldJournal, vol.2015, 2015.

M. Logozzi, High Levels of Exosomes Expressing CD63 and Caveolin-1 in Plasma of Melanoma Patients », vol.4, 2009.

J. Skog, « Glioblastoma microvesicles transport RNA and protein that promote tumor growth and provide diagnostic biomarkers, Nat Cell Biol, vol.10, pp.1470-1476, 2008.

Y. Tanaka, « Clinical impact of serum exosomal microRNA-21 as a clinical biomarker in human esophageal squamous cell carcinoma, Cancer, vol.119, issue.6, pp.1159-1167, 2013.

. «-rapport-leem-enquete-attractivité, , 2014.

D. Sur,

, Clinical Trials Market Size Worth $65.2 Billion By 2025 | CAGR: 5.7% »

D. Sur,

A. Sertkaya, H. Wong, A. Jessup, and T. Beleche, « Key cost drivers of pharmaceutical clinical trials in the United States, Clinical Trials, vol.13, issue.2, pp.117-126, 2016.

T. J. Hwang, D. Carpenter, J. C. Lauffenburger, B. Wang, J. M. Franklin et al.,

. Kesselheim, Failure of Investigational Drugs in Late-Stage Clinical Development and Publication of Trial Results, vol.176, pp.1826-1833, 2016.

H. L. Pearce, K. L. Blanchard, and C. A. Slapak, « Failure modes in anticancer drug discovery and development, Cancer Drug Design and Discovery, pp.424-435, 2008.

L. Amiri-kordestani and T. Fojo, « Why Do Phase III Clinical Trials in Oncology Fail so Often?, J Natl Cancer Inst, vol.104, issue.8, pp.568-569, 2012.

H. K. Gan, B. You, G. R. Pond, and E. X. Chen, « Assumptions of Expected Benefits in Randomized Phase III Trials Evaluating Systemic Treatments for Cancer, J Natl Cancer Inst, vol.104, issue.8, pp.590-598, 2012.

J. A. Dimasi and H. G. Grabowski, Economics of New Oncology Drug Development », JCO, vol.25, pp.209-216, 2007.

D. L. Jardim, E. S. Groves, P. P. Breitfeld, and R. Kurzrock, « Factors associated with failure of oncology drugs in late-stage clinical development: A systematic review, Cancer Treatment Reviews, vol.52, pp.12-21, 2017.

, Top Clinical Trial Failures of 2016 | The Lists, vol.13

I. Astsaturov, « Future Clinical Trials: Genetically Driven Trials, vol.26, issue.4, pp.791-797, 2017.

K. Hayashi, S. Masuda, and H. Kimura, Impact of biomarker usage on oncology drug development, vol.38, pp.62-67, 2013.

F. Prinz, T. Schlange, and K. Asadullah, « Believe it or not: how much can we rely on published data on potential drug targets? », Nature Reviews Drug Discovery, vol.10, issue.9, p.712, 2011.

C. G. Begley and L. M. Ellis, « Drug development: Raise standards for preclinical cancer research », Nature, 28-mars-2012

D. Sur,

K. K. Jain, « Development of Personalized Medicine, Textbook of Personalized Medicine, pp.589-654, 2015.

L. A. Renfro, M. An, and S. J. Mandrekar, « Precision Oncology: A New Era of Cancer Clinical Trials, Cancer Lett, vol.387, pp.121-126, 2017.

D. J. Slamon, « Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2 », New England Journal of Medicine, vol.344, issue.11, pp.783-792, 2001.

C. and L. Tourneau, « Randomised proof-of-concept phase II trial comparing targeted therapy based on tumour molecular profiling vs conventional therapy in patients with refractory cancer: results of the feasibility part of the SHIVA trial », Br J Cancer, vol.111, issue.1, pp.17-24, 2014.

C. and L. Tourneau, « Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, openlabel, proof-of-concept, randomised, Lancet Oncol, vol.16, issue.13, pp.1324-1334, 2015.

L. A. Renfro, H. Mallick, M. An, D. J. Sargent, and S. J. Mandrekar, Clinical trial designs incorporating predictive biomarkers, vol.43, pp.74-82, 2016.

Y. «-remise and . Levy, France médecine génomique, 2025.

D. Sur,

«. Les-plateformes-de-france-génomique--france-génomique,

D. Sur,

«. Unicancer--, Deux plateformes de séquençage très haut débit pour la médecine génomique

I. F. Tannock and J. A. Hickman, « Limits to Personalized Cancer Medicine, New England Journal of Medicine, vol.375, pp.1289-1294, 2016.

S. Kim, « Drifts in ADCC-related quality attributes of Herceptin®: Impact on development of a trastuzumab biosimilar, MAbs, vol.9, issue.4, pp.704-714, 2017.

B. Petricevic, « Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patients, J Transl Med, vol.11, p.307, 2013.

, « Dépistage et détection précoce -Professionnels de santé | Institut National Du Cancer

D. M. Harper and L. R. Demars, « HPV vaccines -A review of the first decade, Gynecologic Oncology, vol.146, issue.1, pp.196-204, 2017.

. Professeur-hervé-fridman, Faculté de médecine Paris Descartes -Ethique et cancer : la médecine personnalisée

-. «-infrastructure and . Biobanques-»,

D. Sur,

«. The, Cancer Genome Atlas Home Page », The Cancer Genome Atlas -National Cancer Institute

. «-international-cancer-genome and . Consortium,

R. A. Burrell, N. Mcgranahan, J. Bartek, and C. Swanton, « The causes and consequences of genetic heterogeneity in cancer evolution, Nature, vol.501, 2013.

C. E. Meacham and S. J. Morrison, Nature, vol.501, 2013.

J. A. Dimasi, L. Feldman, A. Seckler, and E. A. Wilson, Trends in Risks Associated With New Drug Development: Success Rates for Investigational Drugs, vol.87, pp.272-277, 2010.

M. Schwaederle, « Association of Biomarker-Based Treatment Strategies With Response Rates and Progression-Free Survival in Refractory Malignant Neoplasms: A Meta-analysis, JAMA Oncol, vol.2, issue.11, pp.1452-1459, 2016.

M. Wang, B. Yin, H. Y. Wang, and R. Wang, Current advances in T-cell-based cancer immunotherapy, vol.6, pp.1265-1278, 2014.

D. Lacombe and Y. Liu, « The future of clinical research in oncology: where are we heading to?, Chinese Clinical Oncology, vol.2, issue.1, 2013.

J. Kushner, « The ethics of personalized medicine, Personalized Medicine Universe, vol.3, pp.42-45, 2014.